Biocardia Stock Market Value
| BCDA Stock | USD 1.19 0.01 0.85% |
| Symbol | Biocardia |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value - what Biocardia's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Biocardia 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biocardia's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biocardia.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Biocardia on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Biocardia or generate 0.0% return on investment in Biocardia over 90 days. Biocardia is related to or competes with Creative Medical, Aprea Therapeutics, Acurx Pharmaceuticals, Kiora Pharmaceuticals, HCW Biologics, Alzamend Neuro, and Adial Pharmaceuticals. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for car... More
Biocardia Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biocardia's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biocardia upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 17.38 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 5.93 |
Biocardia Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocardia's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biocardia's standard deviation. In reality, there are many statistical measures that can use Biocardia historical prices to predict the future Biocardia's volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.11) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biocardia's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biocardia February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.10) | |||
| Mean Deviation | 2.61 | |||
| Coefficient Of Variation | (6,409) | |||
| Standard Deviation | 3.67 | |||
| Variance | 13.49 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 17.38 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 5.93 | |||
| Skewness | 0.5056 | |||
| Kurtosis | 2.81 |
Biocardia Backtested Returns
At this point, Biocardia is moderately volatile. Biocardia secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Biocardia, which you can use to evaluate the volatility of the firm. Please confirm Biocardia's Standard Deviation of 3.67, insignificant risk adjusted performance, and Mean Deviation of 2.61 to double-check if the risk estimate we provide is consistent with the expected return of 6.0E-4%. The firm shows a Beta (market volatility) of 0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biocardia's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biocardia is expected to be smaller as well. Biocardia right now shows a risk of 3.78%. Please confirm Biocardia treynor ratio, skewness, rate of daily change, as well as the relationship between the value at risk and accumulation distribution , to decide if Biocardia will be following its price patterns.
Auto-correlation | 0.75 |
Good predictability
Biocardia has good predictability. Overlapping area represents the amount of predictability between Biocardia time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biocardia price movement. The serial correlation of 0.75 indicates that around 75.0% of current Biocardia price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.75 | |
| Spearman Rank Test | -0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out Biocardia Correlation, Biocardia Volatility and Biocardia Performance module to complement your research on Biocardia. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Biocardia technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.